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Hypoxanthine guanine phosphoribosyltransferases
(HGPRTs) (EC 2.4.2.8) catalyze the conversion of
6-oxopurine bases to their respective mononucleotides,
the phosphoribosyl group being derived from phos-
phoribosyl pyrophosphate (PRPP) in a Mg2+-requiring
reaction [1] (Fig. 1A). Most parasitic protozoa do
not have the de novo purine nucleotide biosynthetic
pathway and rely exclusively on the salvage of pre-
formed host purines for their survival [2,3]. Studies
by Berman et al. show that viability of intraerythro-
cytic Plasmodium falciparum is compromised in the
presence of xanthine oxidase and highlight hypo-
xanthine as the key precursor salvaged for purine
nucleotide synthesis [4]. Although weak activities
have been reported for adenosine kinase and adenine
phosphoribosyltransferase in parasite lysate [5,6],
sequences with homology to these enzymes have not
been identified in the parasite genome [7]. Purine
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Hypoxanthine guanine phosphoribosyltransferases (HGPRTs) catalyze the
conversion of 6-oxopurine bases to their respective nucleotides, the phos-
phoribosyl group being derived from phosphoribosyl pyrophosphate.
Recombinant Plasmodium falciparum HGPRT, on purification, has negli-
gible activity, and previous reports have shown that high activities can be
achieved upon incubation of recombinant enzyme with the substrates hypo-
xanthine and phosphoribosyl pyrophosphate [Keough DT, Ng AL, Winzor
DJ, Emmerson BT & de Jersey J (1999) Mol Biochem Parasitol 98, 29–41;
Sujay Subbayya IN & Balaram H (2000) Biochem Biophys Res Commun
279, 433–437]. In this report, we show that activation is effected by the
product, Inosine monophosphate (IMP), and not by the substrates. Studies
carried out on Plasmodium falciparum HGPRT and on a temperature-
sensitive mutant, L44F, show that the enzymes are destabilized in the pres-
ence of the substrates and the product, IMP. These stability studies suggest
that the active, product-bound form of the enzyme is less stable than the
ligand-free, unactivated enzyme. Equilibrium isothermal-unfolding studies
indicate that the active form is destabilized by 2–3 kcalÆmol)1 compared
with the unactivated state. This presents a unique example of an enzyme
that attains its active conformation of lower stability by product binding.
This property of ligand-mediated activation is not seen with recombinant
human HGPRT, which is highly active in the unliganded state. The reversi-
bility between highly active and weakly active states suggests a novel
mechanism for the regulation of enzyme activity in P. falciparum.
Abbreviations
HGPRT, hypoxanthine guanine phosphoribosyltransferase; IMP, inosine monophosphate; PfHGPRT, Plasmodium falciparum HGPRT; PRPP,
a-D-phosphoribosyl pyrophosphate.
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analogs, by serving probably as subversive sub-
strates of HGPRT, have been shown to be lethal to
P. falciparum in culture [8], making HGPRT a prom-
ising drug target. Further evidence for the essentiality
of HGPRT to the parasite also comes from the
observed antiparasitic activity of antisense oligonucleo-
tides of HGPRT mRNA [9]. However, it should be
noted that various other studies have revealed that
short oligonucleotides could also exert their action,
at high concentrations, as nonspecific polyanions
blocking merozite invasion of the erythrocyte [10–13].
HGPRT is also of importance to the host, with the
absence and the deficiency of HGPRT manifesting as
Lesch–Nyhan syndrome and gouty arthritis, respect-
ively [14,15].
The kinetic mechanism of HGPRT is ordered bi-bi,
with PRPP binding first followed by the purine base
[16,17]. Product formation has been postulated to
occur through a ribo-oxocarbonium ion intermediate
[18]. Subsequent to product formation, pyrophosphate
release precedes nucleotide release. This mechanism
has been elucidated for the human [16], schistosomal
[17], Tritrichomonas foetus [19] and Trypanosoma cruzi
[20] HGPRTs, and is also probably true for the P. fal-
ciparum HGPRT.
Human and P. falciparum HGPRTs share a
sequence identity of 44% and a similarity of 76%. The
structures of both of these enzymes, in complex with
transition-state analogues, pyrophosphate and two
Mg2+ ions, solved to high resolution (2 A˚), superpose
with an rmsd of  1.7 A˚ [21,22] (Fig. 1B). The struc-
ture comprises core and hood subdomains, with a cleft
between these subdomains forming the active site. The
residues contacting the active-site ligands are identical
in the two enzymes. Both enzymes are active as homo-
tetramers. Despite this high degree of sequence and
structural similarity, these HGPRTs differ significantly
in their properties. One difference is in the substrate
specificity, the parasite enzyme having the ability to
catalyze the phosphoribosylation of xanthine, in addi-
tion to hypoxanthine and guanine [23]. Substrate spe-
cificity has been shown to be modulated by both
active-site and nonactive-site mutations. Mutation of
Asp193 to Asn in the active site of T. foetus HGPRT
results in the loss of activity on xanthine [24]. Muta-
tion of Phe36 (a residue distal from the active site in
human HGPRT) to Leu results in an enzyme with
activity on xanthine [25]. A chimeric HGPRT, with the
N-terminal region in the human enzyme replaced by
that of P. falciparum HGPRT (PfHGPRT), also has
xanthine phosphoribosylation activity [26].
Another difference between these two homologs lies
in the behaviour of the purified recombinant enzymes.
The recombinant human HGPRT is highly active
upon purification, even in the absence of substrates
[16]. This is also true of T. cruzi HGPRT [27]. In the
case of the Schistosoma mansoni and Toxoplasma
gondii HGPRTs, the presence of PRPP stabilizes the
enzyme [28,29]. In contrast, the purified P. falciparum
HGPRT has negligible activity [30,31]. The presence
of PRPP alone does not stabilize enzyme activity [30].
The lack of activity has hampered detailed biochemi-
cal characterization of the parasite enzyme and raised
doubts about the necessity of the enzyme to the para-
site [32]. Keough et al., for the first time, showed that
the incubation of recombinant PfHGPRT with the
substrates hypoxanthine and PRPP, results in a large
increase in the specific activities of the enzyme [30].
Oligomerization is also a necessary, but insufficient,
condition for activation, with activation being most
stable under conditions in which the enzyme is a tetra-
mer. PfHGPRT is a tetramer in low-ionic-strength
buffers (10 mm potassium phosphate, pH 7.0). High
specific activity can be obtained only upon addition
of the substrates to this tetrameric enzyme [30,31].
However, the presence of the substrates does not lead
A
B
Fig. 1. (A) The reaction catalyzed by HGPRT. (B) Superposition of
the transition state analogue, Mg2+, and pyrophosphate bound
structures of P. falciparum (PDB code 1CJB, black) and human
(PDB code 1BZY, grey) HGPRTs. The ligands (from 1CJB), shown
in stick representation, define the active site. L44 of PfHGPRT is
shown in ball-and-stick representation.
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to activation when the enzyme is a dimer (10 mm
potassium phosphate, 1.2 m KCl) [30]. The reported
structure of PfHGPRT, in complex with a transition-
state analogue inhibitor, immucillin HP, being simi-
lar to that of other active HGPRTs represents the
active form [22]. Indeed, incubation of unactivated
PfHGPRT with the transition state analogue, immu-
cillin GP, followed by removal of the inhibitor by
dilution, has been reported to lead to an increase in
activity of the enzyme [18].
In this work, we show that the parasite enzyme is
activated by the product of the HGPRT reaction,
Inosine monophosphate (IMP), and not by the sub-
strates hypoxanthine and PRPP. We also examine the
stability of PfHGPRT and a temperature-sensitive
mutant, L44F, in the presence and absence of ligands.
Temperature and chemical denaturation studies of
these enzymes show that the active, product-bound
form of PfHGPRT is less stable than the unactivated
form.
Results
Our attempts at exploring the structural basis for the
xanthine specificity of HGPRTs by random mutagen-
esis led to the identification of a mutant of the human
enzyme, F36L, with xanthine phosphoribosylation
activity. A corresponding mutation in the P. falcipa-
rum enzyme, L44F, led to a decrease in kcat and an
increase in the Km for xanthine [25]. The studies pre-
sented here relate to the activity and stability of wild-
type PfHGPRT and of the L44F mutant.
In vivo stability of PfHGPRT and L44F
The expression of a functional HGPRT can be monit-
ored by using a complementation assay in Escheri-
chia coli S/609 [33,34]. This E. coli strain lacks both
de novo and salvage pathways for purine nucleotide
biosynthesis, and growth in minimal medium supple-
mented with a purine base can be made conditional to
the expression of a functional HGPRT [34]. Figure 2A
shows the ability of PfHGPRT and the mutant, L44F,
to complement the HPRT deficiency in E. coli S/609.
Examination of the ability of PfHGPRT and L44F to
complement the HGPRT deficiency of this strain at
20, 37 and 42 C showed that the L44F mutant is
temperature sensitive. While PfHGPRT permits the
growth of these cells at all three temperatures, L44F
does so only at 20 and 37 C. Cells transformed with
the L44F expression construct in minimal medium sup-
plemented with the purine base hypoxanthine do not
grow at 42 C (Fig. 2A).
Although wild-type PfHGPRT hyper-expresses in
S/609, the expression of L44F cannot be detected in
Coomassie stained gels, raising the possibility that the
failure of L44F to complement could be due to lack of
its expression. The expression and stability of both of
these proteins were therefore examined by detecting
the residual amount of protein after translational
arrest with chloramphenicol (Fig. 2B). While the wild-
type enzyme was found to be stable at all three tem-
peratures examined, L44F, although expressed, was
completely degraded within 1 h of translational arrest
at 37 and 42 C. The mutant protein was, however,
found to be stable at 20 C. The temperature sensitiv-
ity of the mutant in vivo thus arises as a result of the
proteolytic degradation of the protein, probably owing
to misfolding at higher temperatures.
B
A
Fig. 2. In vivo temperature stability of PfHGPRT and L44F. (A)
Growth, at the indicated temperatures, in minimal medium supple-
mented with hypoxanthine, of E. coli S/609 transformed with
PfHGRPT (open bars) and L44F (closed bars) expression constructs
in pTrc99A. (B) Residual levels of PfHGPRT and L44F, at different
incubation temperatures, in S/609 after translational arrest with
chloramphenicol. Protein expression was induced by the addition of
isopropyl thio-b-D-galactoside and allowed to proceed for 4 h, trans-
lation was arrested by the addition of chloramphenicol, and residual
protein in aliquots withdrawn at different time-points was detected
by western blots probed with polyclonal antibodies against
PfHGPRT. Lanes 1–6 represent samples withdrawn at 0, 10, 30,
60, 180 and 300 min, respectively, after the addition of
chloramphenicol. M indicates purified PfHGPRT used as a marker.
Expression analysis was repeated four times. The temperatures
indicated are for both A and B.
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Activation of PfHGPRT
Recombinant PfHGPRT is highly soluble and can be
readily purified to homogeneity from E. coli expression
systems [30,31]. Figure 3 compares the far-UV CD
spectrum of this purified protein with that of recom-
binant human HGPRT. Also shown is the CD spec-
trum of the L44F mutant of PfHGPRT. The spectra
show that all three enzymes are largely folded with
similar secondary structural composition. Despite this,
PfHGPRT and the L44F mutant show negligible
activity [25,30,31], while the human enzyme has high
activity [16]. Previous reports have shown that consid-
erable improvement in specific activity can be obtained
upon incubation of this folded, but largely inactive,
enzyme with the substrates hypoxanthine and PRPP in
10 mm potassium phosphate buffer, pH 7.0, conditions
under which the enzyme is a tetramer [30,31]. These
studies also show that tetramer formation is a neces-
sary, but insufficient, condition for obtaining stable,
high activities [30]. L44F, a mutant of the parasite
enzyme, also exhibited this property, with high specific
activity obtained only upon incubation with the sub-
strates. The activation process is also accompanied by
the disappearance of a lag phase that is seen in assays
carried out with the unactivated enzyme, suggesting a
role for a substrate-induced conformational change in
the activation process (data not shown).
Figure 4 shows the specific activity of the wild-type
enzyme for xanthine phosphoribosylation after incuba-
tion with various combinations of ligands. It should be
noted here that specific activities were determined by
using a continuous spectrophotometric assay. Initial
rates were determined from the difference in absorb-
ance, at different time-points, on the linear phase of the
reaction. Any contribution to the absorbance from the
ligand carried over (< 0.48 lm) into the assay together
with the activated enzyme would not affect the specific
activities presented. The presence of ligands at these
concentrations in the assay did not increase the reac-
tion rates of the unactivated enzyme. Surprisingly, acti-
vation was observed only upon incubation with PRPP
and hypoxanthine, and not with guanine and xanthine,
the other purine substrates of the enzyme. Although no
metal ions were added to the activation mix, the pres-
ence of EDTA, in addition to hypoxanthine and PRPP,
prevented activation. As the binding of PRPP to
HGPRT is dependent on the presence of Mg2+ ions
[21,22], EDTA could hamper PRPP binding. This sug-
gests that the presence of trace metal ions, probably
copurifying with the enzyme, are necessary for the
activation process. This also raises the possibility that
incubation with the substrates hypoxanthine and
PRPP, albeit in the absence of additional Mg2+, might
be accompanied by formation of the product, IMP.
Product formation in the activation mix was therefore
monitored by the use of 3H-labelled hypoxanthine in
Fig. 4. Specific activity of PfHGPRT after incubation with the indica-
ted ligands. Specific activity for xanthine phosphoribosylation was
measured after incubation of PfHGPRT with the ligands for 12 h at
4 C. Ligand concentrations, when used, were as follows: PRPP,
200 lM; hypoxanthine and IMP, 60 lM; xanthine and XMP, 120 lM;
and EDTA, 1 mM, at a protein concentration of 30 lM in 10 mM
potassium phosphate, pH 7.0, containing 20% (v ⁄ v) glycerol and
5 mM dithiothreitol. Unactivated enzyme refers to the incubation of
enzyme in the absence of the ligands under the same buffer condi-
tions.
Fig. 3. Far-UV CD spectra of human HGPRT (s),PfHGPRT (n) and
L44F (d), in 10 mM potassium phosphate, pH 7.0.
J. Raman et al. The active form of Plasmodium falciparum HGPRT
FEBS Journal 272 (2005) 1900–1911 ª 2005 FEBS 1903
the activation process. Surprisingly, significant amounts
of IMP were detected, although no exogenous metal
ions were added to the activation mix. The concentra-
tion of IMP formed correlated directly with the degree
of activation (Table 1). Indeed, rapid activation could
be achieved with IMP. While incubation with hypoxan-
thine and PRPP took up to 24 h to yield stable activit-
ies, IMP could activate the enzyme within 3 h. The final
levels of activity obtained in either case were, however,
similar. Although substoichiometric IMP concentra-
tions did not lead to complete activation, co-operative
activation of the HGPRT homotetramer by IMP bind-
ing to one of the subunits cannot be ruled out. Surpris-
ingly, despite the fact that guanosine monophosphate
(GMP) and xanthosine monophosphate (XMP) are also
products of the PfHGPRT reaction, these nucleotides
do not activate the enzyme. The activation process is
also completely reversible. The loss of activity, on stor-
age, of some preparations of the enzyme after activation
could be traced to the presence of a contaminating
phosphatase activity in these preparations. The addition
of fresh IMP to these preparations restored the enzyme
activity to maximal levels. In the following stability
studies, activated enzyme refers to the product (IMP)-
bound, highly active form of the enzyme.
Effect of reaction temperature on activity
As the L44F mutant is temperature sensitive, the activ-
ity of the mutant at elevated temperatures can be
compared to that of the wild-type enzyme. To investi-
gate this, we monitored the phosphoribosylation activ-
ity of activated enzyme in reactions initiated by adding
the enzyme to preheated assay buffer. Consistent with
its temperature sensitivity, the temperature optima for
the reactions catalyzed by L44F were lower than that
of the wild-type enzyme. Surprisingly, in the case of
both enzymes, the temperature optimum for the xan-
thine reaction was  10 C lower than that for the
hypoxanthine reaction (Fig. 5A,B). Under similar
assay conditions, the xanthine and hypoxanthine phos-
phoribosylation activities of a xanthine active mutant
of human HGPRT, F36L, were found to increase line-
arly with temperature (Fig. 5C). This differentiation
between the substrates hypoxanthine and xanthine is
therefore a property of the parasite enzyme. These
data gave the first indication that PfHGPRT could be
destabilized by its substrates.
Temperature stability, as monitored by CD
The temperature vs. activity profiles of both
PfHGPRT and the L44F mutant suggested that the
stability of the enzymes in the presence of xanthine
and hypoxanthine might be different. This possibility
was investigated by monitoring, by CD, the loss of sec-
ondary structure in the presence of the substrates as a
function of temperature. Initial measurements were
carried out with unactivated protein incubated for only
30 min with the substrates. Surprisingly, changes in the
stability of the proteins were evident, even at the level
of the secondary structure. While the presence of either
hypoxanthine or xanthine, along with PRPP, altered
the melting behaviour of both enzymes after only
30 min of incubation, the effect was more pronounced
in the case of the L44F mutant. The sharp, single
transition with a Tm of 64.3 C, in the melting pro-
file of unliganded (unactivated) L44F, indicative of
Table 1. Specific activity of PfHGPRT and concentration of IMP
formed at different time-points during activation.
Specific activity
(nmolÆmin)1Æmg)1)
Time
(h)
[IMP]
(lM)
1446 6 8
5224 48 38
Fig. 5. Specific activity, at different incubation temperatures, expressed as the percentage of activity at room temperature of (A) PfHGPRT,
(B) L44F and (C) F36L mutant of human HGPRT on hypoxanthine (s) and xanthine (h). Initial rates were measured by the addition of
enzyme to preheated assay buffer by using a spectrophotometer equipped with a water-jacketed cell holder. The curves are representative
of two independent experiments with different batches of enzyme.
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co-operativity, altered to a multistate transition in the
presence of hypoxanthine and PRPP. In the presence
of xanthine and PRPP, the Tm dropped to 57 C,
although the transition profile remained unaltered
(Fig. 6A). The melting profiles were not altered in the
presence of either PRPP or the purine base alone.
These melting profiles suggest that the enzyme is desta-
bilized not only in the presence of xanthine and PRPP,
but also on formation of the enzyme ⁄hypoxanthine ⁄
PRPP ternary complex, conditions that represent those
used for activation of the enzymes.
Pronounced changes in stability of the wild-type
enzyme were observed when the stability was monit-
ored after activation of the enzyme. The melting
profiles of the wild-type enzyme, after activation, by
incubation with either hypoxanthine and PRPP or
IMP were compared with those of the unactivated
enzyme (Fig. 6B). For these measurements, the enzyme
(after overnight activation) was diluted into buffers
that represent the initial condition of activation
(10 mm potassium phosphate, pH 7.0, containing
either 60 lm IMP or 30 lm hypoxanthine and 100 lm
PRPP). The melting profile in the presence of hypo-
xanthine and PRPP thus represents that of an
enzyme ⁄PRPP ⁄hypoxanthine ternary complex of the
activated enzyme, while the melting profile in the pres-
ence of IMP represents that of the activated enzyme
bound to IMP. The melting temperature of the activa-
ted enzyme, under both of these conditions, is signifi-
cantly lower than that of the unactivated protein
(Fig. 6B). The presence of hypoxanthine and PRPP
destabilizes the protein more than the presence of
IMP. Together, these melting profiles clearly indicate
that the thermal stability of the activated (ligand
bound) enzyme is lower than that of the unactivated
(unliganded) protein.
Effect of temperature on the equilibrium between
high and low activity states
Activated PfHGPRT, in the presence of IMP, was pre-
incubated at different temperatures, and the specific
activity of aliquots withdrawn at different time-points
was determined at room temperature. The specific
activity as a function of preincubation time at different
temperatures is shown in Fig. 7A. A sharp decrease in
the activity to a value where it is stable for many
hours is seen at all temperatures. The value at which
the activity stabilizes decreases with increase in prein-
cubation temperature. The value at this plateau, even
at 50 C, is greater than the specific activity of the
unactivated enzyme. The drop in activity was found to
be completely reversible, with activity returning to ini-
tial levels upon lowering the temperature to 4 C. The
existence of stable plateaus suggested an equilibrium
process between forms of low and high activity. The
Keq at each temperature was determined by using a
value corresponding to the activity of the enzyme incu-
bated at 4 C as the specific activity of the fully activa-
ted enzyme, and the value obtained for the enzyme
immediately after purification as the specific activity of
the unactivated enzyme. The ratio of the concentration
of the two species (weakly active ‘I’ and highly active
‘A’) can be calculated as:
Keq ¼ x=ð1 xÞ;
where x is the fraction of A, and
A
B
Fig. 6. Temperature denaturation of (A) L44F in the absence of lig-
ands (1) and in the presence of 100 lM a-D-phosphoribosyl pyro-
phosphate (PRPP) and either 30 lM hypoxanthine (2) or 60 lM
xanthine (3). (B) Temperature denaturation of PfHGPRT in the
absence of any ligand (1), in the presence of 60 lM IMP (2), or in
the presence of 30 lM hypoxanthine and 100 lM PRPP (3).
PfHGPRT was preincubated for 15 h at 4 C in the presence of
IMP (2) or hypoxanthine and PRPP (3), before the measurements
were made. Denaturation of 2.4 lM protein in 10 mM potassium
phosphate buffer, pH 7.0, was monitored by following the CD sig-
nal at 220 nm.
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x ¼ ðSAÞT  ðSAÞI=ðSAÞA  ðSAÞI;
for the equilibrium I+(A, where (SA)T is the specific
activity at any temperature T, (SA)I is the specific
activity of the unactivated enzyme, and (SA)A is the
specific activity of the fully activated enzyme.
A van’t-Hoff plot (inverse of temperature vs. ln Keq)
gives a negative value for DH for the I fi A transition
(Fig. 7B).
Equilibrium isothermal unfolding
The irreversibility of the thermal melting prevents
evaluation of the free energies of the activated and
unactivated states. Both unactivated and activated
PfHGPRT are remarkably stable to denaturation by
urea. A significant amount of secondary structure is
retained, even at a urea concentration of 8 m.
Unfolding studies on the activated and unactivated
enzyme were therefore carried out with guanindium
chloride. Equilibrium isothermal unfolding with guan-
idinium chloride at 25 C placed the free energies of
unfolding of the unactivated and activated forms of
PfHGPRT at 8.8 ± 0.7 and 6.3 ± 0.2 kcalÆmol)1,
respectively. By comparison to the unactivated form,
the activated form is thus destabilized by 2–3 kcalÆ
mol)1 at 25 C (Fig. 8). As the free energy for this
transformation is positive, while the enthalpy change
for I fi A is negative, the activation of PfHGPRT is
entropically unfavorable.
Discussion
The observations described above suggest that the con-
formation of PfHGPRT on purification is one of high
Fig. 8. Free energy for guanidinium chloride (GdmCl) denaturation
of unactivated and activated PfHGPRT. Equilibrium unfolding at
25 C, of activated (s) and unactivated (h) PfHGPRT, at different
concentrations of the denaturant, was followed as the CD signal at
220 nm, and the free energy of unfolding was calculated after cor-
rection for linear folded and unfolded baselines. The difference
between the free energy of the two states is the difference
between the value extrapolated to 0 M denaturant. The graph pre-
sents data from three independent experiments. Denaturation of
the unactivated enzyme was carried out in 10 mM potassium phos-
phate, pH 7.0, while the activated enzyme was denatured in the
presence of 60 lM IMP, both at a protein concentration of 10 lM.
The inset shows the proposed energy landscape for the activation
process. D, I and A refer to the denatured, weak activity and high
activity states of PfHGPRT, respectively. The numbers indicated
are free energies derived from equilibrium unfolding studies. See
the text for standard error values.
A
B
Fig. 7. Effect of temperature on the equilibrium between the high
and low activity states of PfHGPRT. (A) Effect of preincubation of
activated PfHGPRT at different temperatures on the specific activity
for xanthine phosphoribosylation measured at 28 C. The enzymes
were first activated by overnight incubation with 60 lM IMP at 4 C.
Data are representative of three independent experiments. Similar
profiles were obtained with L44F. (B) van’t-Hoff plot for determin-
ation of enthalpy change for the equilibrium I )* A (weakly act-
ive )* highly active). The Keq was calculated by using the specific
activities recorded at the plateaus at each temperature in (A).
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stability, albeit low activity. Incubation with (and
binding of) the substrates ⁄products alters the confor-
mation to a less stable state. This state of lower stabil-
ity – a metastable state – is the active form of the
enzyme. The activity vs. temperature profiles of both
PfHGPRT and L44F show that they are destabilized
in the presence of xanthine as compared to hypoxan-
thine, an indication of substrate-induced destabiliza-
tion. The denaturation profiles of the proteins under
activation conditions clearly show that the activated
form (IMP bound) is less stable than the unactivated
protein. Taken together, these data allow a description
of the energy landscape for the activation (Fig. 8,
inset), which places the active form 2–3 kcalÆmol)1
higher than the inactive form.
Metastable active states are infrequently mentioned
in the literature. Examples include the class of prote-
ase inhibitors, serpins, which lose their inhibitory
activity when stabilizing mutations are introduced
[35,36]. A well-documented example is the a-lytic pro-
tease, the active metastable state of which is achieved
with the aid of a pro-segment [37–39]. In PfHGPRT,
the product of the reaction, IMP, seems to play a role
similar to that of the pro-segment. However, unlike
the a-lytic protease that is trapped in the metastable
state by a large kinetic barrier [39], PfHGPRT readily
reverts to the stable, weakly active form on removal of
IMP. The active form, free of IMP, could not be isola-
ted despite repeated attempts. However, the activated
enzyme can proceed through repeated cycles of cata-
lysis on all three substrates (hypoxanthine, guanine
and xanthine), even after IMP is diluted out in the
assay buffer. The process of activation and catalysis is
schematically represented in Fig. 9. Although co-oper-
ativity has not been observed in HGPRTs, the binding
of IMP to one subunit in the inactive tetramer of
PfHGPRT, and thus triggering a conformational
switch to the active form in the other subunits, could
underlie the process of activation. The activated
enzyme, capable of binding PRPP and hypoxanthine,
is then catalytically competent. Instability of the active
form of PfHGPRT indicates that this form is strained
and slips back to the inactive state once IMP is
removed. This feature of PfHGPRT could stem from
its quaternary structure, and differences in interface
interactions may be responsible for suppressing co-
operativity in other HGPRTs. However, it is interest-
ing to note that co-operativity in PRPP binding has
been observed in the human HGPRT mutants, K68A
and D194E, with Hill coefficients of 1.9 and 2.3,
respectively, while the wild type is nonco-operative
[40,41]. A possible structural basis for co-operativity
comes from the crystal structures of the trypanosomal
and T. gondii HGPRTs [42–44]. In the crystal struc-
ture of trypanosomal HGPRT, K68 interacts with
PRPP and with residues in the neighbouring subunit
of the dimer. Elimination of these interactions in the
mutant K68A has been suggested to play a role in the
observed co-operativity. In the high-resolution struc-
ture of the T. gondii HGPRT complexed to XMP and
pyrophosphate, a network of hydrogen bonds, direct
and water-mediated, linking the active site in one sub-
unit with that in the adjacent subunit of the tetramer,
also provides a structural basis for the co-operativity
seen in the mutants. The only available structure of
PfHGPRT is of a complex with a transition state ana-
log representing the active state. Structures of unligan-
ded and different substrate ⁄product complexes should
Fig. 9. Schematic representation of the
process of activation and catalysis by
PfHGPRT. IMP binding switches the
enzyme from a weak to a high activity
state, and its removal reverts the enzyme
back to weak activity. Our model shows
that IMP binding to one subunit may be
sufficient to retain the high activity state of
the tetramer, with active sites in the
remaining subunits available for catalysis.
The enzyme remains active during the
assay owing to the faster rate of a-D-phos-
phoribosyl pyrophosphate (PRPP) ⁄ hypoxan-
thine binding (k1) compared to the rate of
conversion to the weakly active state on
IMP release (k2). Hyp, hypoxanthine; PPi,
pyrophosphate. ‘Active’ refers to the high
activity state of PfHGPRT.
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provide insights into the mechanism of activation of
PfHGPRT.
Native state metastability has been proposed to have
varied biological significance. In the a-lytic protease, it
represents a mechanism for increasing protease longev-
ity [37,38]. The decreased conformational flexibility of
the native metastable state of the mature protease pro-
tects it from proteolytic degradation [39]. In the case of
the protease inhibitors, serpins, metastability has been
suggested to be a mechanism for regulation, presumably
facilitating a conformational switch allowing inhibition
[36]. A similar role has also been suggested for hemaggu-
tinin [45] and some viral capsid proteins [46,47], where
the metastability permits the conformational switch to a
fusion active state. In the phosphoribulokinase ⁄glyceral-
dehyde-3-phosphate dehydrogenase complex, phospho-
ribulokinase is in a metastable state immediately after
dissociation from the complex and relaxes to a stable
state of lower activity, with time, after dissociation [48].
The property of ligand-induced conformational
changes to an active state of lower stability is unique
to PfHGPRT and is not seen with the human homo-
log. It provides a mechanism for fast interconversion
between a form of low activity and one of high activ-
ity, thus providing a means for regulating enzyme
activity in vivo. However, the precise role of such a
regulatory process is not obvious and requires investi-
gation. It is also possible that PfHGPRT may be asso-
ciated with other cellular proteins in vivo, allowing
substrate channeling with the association maintaining
the protein in the active conformation. The absence of
the de novo pathway in the malaria parasite entails a
central role for HGPRT in the parasites’ purine meta-
bolism. The requirements of regulation and activity
that this unique position would impose, especially in
context of the high A ⁄T content (> 70% AT) of the
P. falciparum genome [49], may necessitate novel
modes for control of enzyme activity. Complete bio-
chemical characterization of all the enzymes of the
purine salvage pathway in P. falciparum should pro-
vide insight into the role of IMP in regulating purine
metabolism in the parasite.
Experimental procedures
Restriction enzymes, Taq DNA polymerase, T4 DNA ligase
and other molecular biology reagents were purchased from
Bangalore Genei Pvt. Ltd (Bangalore, India) or from MBI
Fermentas (V. Graiciuno, Vilnius, Lithuania) and used
according to the manufacturers’ instructions. The E. coli
strain S/609 (ara, Dpro-gpt- lac, thi, hpt, pup, purH,J, strA)
was a gift from Dr Per Nygaard, University of Copenhagen
(Copenhagen, Denmark). All chemicals used in the assays
were from Sigma Chemical Company (St. Louis, MO, USA)
and media components were from HiMedia Laboratories
Ltd (Mumbai, India). Purine base stocks were made in
0.4 m NaOH, and all other solutions were made in water.
Functional complementation
Complementation studies were carried out by using the
E. coli strain S/609 (ara, Dpro-gpt-lac, thi, hpt, pup, purH,J,
strA) [33] transformed with the expression constructs of
human HGPRT, PfHGPRT or L44F in pTrc99A. Conditions
used for complementation analysis were as described previ-
ously [34]. Briefly, cells grown overnight in LB (Luria–
Bertani) medium containing ampicillin (concentration
100 lg ml)1) and streptomycin (concentration 25 lg ml)1),
were washed with, and resuspended in, 1· M9 salt solution.
A 1% (v ⁄ v) inoculum of these cells was added to minimal
medium containing 1· M9 salts, 1 mm MgSO4, 0.1 mm
CaCl2, 1 mm thiamine hydrochloride, 1 mm proline, 0.2%
(w ⁄ v) glucose, 0.3 mm isopropyl thio-b-d-galactoside,
25 lgÆmL)1 streptomycin, 100 lgÆmL)1 ampicillin and
0.5 mm hypoxanthine, guanine or xanthine. The cells were
cultured for 15 h at 37 C and the attenuance (D) at 600 nm
was recorded. All experiments were repeated at least three
times.
Determination of in vivo stability
For determination of the in vivo stability of PfHGPRT and
L44F, S/609 cells containing the expression constructs of
these proteins in pTrc99A were grown to reach a D600 of 0.6
at 20, 37 or 42 C, and protein expression was induced by the
addition of IPTG to a concentration of 1 mm. Protein trans-
lation was arrested by the addition of chloramphenicol to a
concentration of 300 lgÆmL)1 after 4 h of induction. The
residual concentration of expressed proteins, in aliquots
withdrawn at different time-points, was determined by West-
ern blots probed with antibodies to P. falciparum HGPRT.
Protein expression and purification
PfHGPRT was hyper-expressed in E. coli S/609 trans-
formed with the expression construct in the vector pTrc99A
and purified as described previously [31]. Soluble protein
was precipitated with ammonium sulfate and then subjected
to anion exchange chromatography using a Q-Sepharose
column connected to an AKTA-Basic (Amersham Pharma-
cia Biotech, Little Chalfont, Buckinghamshire, UK) HPLC
system, at pH 8.9. The protein eluting at  200 mm NaCl
was then subjected to cation exchange chromatography (at
pH 6.9) using a Resource S column. The bound protein
was eluted with a linear NaCl gradient.
The L44F mutant was cloned into the vector pET23d and
expressed in E. coli BL21(DE3) [F) ompT hsdSB(rB
) mB)
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gal dcm (DE3)]. Soluble L44F from lysates obtained after
ammonium sulfate fractionation was purified by chromato-
graphy on a Cibacron Blue column followed by anion
exchange chromatography, with both columns being eluted
with increasing gradients of KCl in the presence of 20%
(v ⁄ v) glycerol in all steps [25]. Finally, both wild-type and
L44F enzymes were buffer exchanged, by gel filtration, into
10 mm potassium phosphate, pH 7.0, 20% (v ⁄ v) glycerol and
2 mm dithiothreitol, and were found to be greater than 90%
pure, as judged by SDS ⁄PAGE.
Protein concentrations were determined by using the
method of Bradford, with BSA as a standard [50].
Enzyme activation
PfHGPRT and L44F were activated by incubation with
60 lm hypoxanthine and 200 lm PRPP, or with 60 lm
IMP, at a protein concentration of 30 lm in 10 mm potas-
sium phosphate, pH 7.0, 20% (v ⁄ v) glycerol, 5 mm dithio-
threitol at 4 C. Stable maximal activities were achieved
after  24 h with the hypoxanthine ⁄PRPP activations and
within 3 h for the IMP activations. For the guanidinium
chloride denaturation studies, PfHGPRT was activated at a
concentration of 50 lm with IMP at 120 lm.
Detection of product formation during activation
For detection of product formation during activation, acti-
vation was carried out with 200 lm PRPP and 60 lm
3H-labelled hypoxanthine (specific activity of 3.1 CiÆmol)1)
at a protein concentration of 30 lm in 10 mm potassium
phosphate, pH 7.0, 20% (v ⁄ v) glycerol, containing 5 mm
dithiothreitol. The amount of IMP in activations set up
with 3H-labelled hypoxanthine was determined after the
separation of hypoxanthine and IMP, in aliquots of the
activation mix, by paper chromatography with 2% (v ⁄ v)
sodium dihydrogen ortho-phosphate as the mobile phase.
Spots corresponding to hypoxanthine and IMP were cut
out and the radioactivity corresponding to each was deter-
mined by liquid scintillation.
Enzyme assays
Activation was routinely monitored by measuring, spectro-
photometrically, the specific activity for xanthine phosphori-
bosylation [51]. Assays were carried out in 100 mm
Tris ⁄HCl, pH 7.5, 12 mm MgCl2, containing 200 lm xan-
thine and 1 mm PRPP. Reactions were initiated by the addi-
tion of 2–3 lg of enzyme to 250 lL of the reaction mix, and
XMP formation was monitored as an increase in absorption
at 255 nm. A De value of 3794 m)1Æcm)1 was used to calcu-
late specific activity. Hypoxanthine and guanine phospho-
ribosylation reactions were carried out with a purine base
concentration of 100 lm, and product formation was monit-
ored at 245 and 257.5 nm, respectively. The De values used
were 1900 m)1Æcm)1 and 5600 m)1Æcm)1 for IMP and GMP
formation, respectively [16,30]. Activities at higher tempera-
tures were determined by initiation of the reaction by addi-
tion of activated enzyme to assay buffer containing the
appropriate substrates preheated to the desired temperature.
All reactions were monitored continuously and specific activ-
ities are derived from the difference in absorbance between
two time-points within which the reaction is linear. Activity
was measured by using a Hitachi U2010 spectrophotometer
equipped with a water-jacketed cell holder.
CD measurements
CD measurements were carried out in 10 mm potassium
phosphate, pH 7.0, on a JASCO-715 spectropolarimeter
equipped with a Peltier heating system. The temperature
denaturation was measured at a protein concentration of
2.5 lm with a path length of 10 mm and a heating rate of
1 CÆmin)1. The guanidinium chloride denaturation meas-
urements were carried out at a protein concentration of
10 lm with a path length of 1 mm. Protein unfolding was
monitored as the CD signal at 220 nm. The fraction unfol-
ded (fU) at each point was determined as:
fU ¼ ðhF  hÞ=ðhF  hUÞ;
where hF and hU are the ellipticities of the folded and
unfolded states at each denaturant concentration after cor-
rection for linear baselines, and h is the measured ellipticity
at each denaturant concentration.
The equilibrium constant, K, was calculated from the
following equation:
K ¼ fU=ð1 fUÞ
The free energy change (DG) was calculated from the fol-
lowing equation:
DG ¼ RT lnK
where R is the gas constant (8.3 JÆK)1Æmol)1) and T the abso-
lute temperature. The free energy change in the absence of
denaturant (DG H2O) was determined by fitting to:
DG ¼ ðDGH2OÞ mðdenaturant concentrationÞ
The free energy change for the unfolding of unactivated
and activated PfHGPRT was determined in the absence
and presence, respectively, of IMP. The difference between
these values represents the difference between the stability
of these states.
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